Semaglutide to be investigated for improving depressive symptoms in MDD patients with overweight or obesity
Background
Major Depressive Disorder (MDD) affects millions, often co-occurring with overweight or obesity, which can exacerbate symptoms and complicate treatment. Current antidepressant therapies may have limited efficacy or side effects, particularly in patients with metabolic comorbidities. The GLP-1 receptor agonist semaglutide, known for its weight loss and metabolic benefits, has shown preliminary indications of neuroprotective effects and mood modulation in some contexts, suggesting a potential adjunctive role in improving mood in this specific patient population. Investigating this link could offer a novel therapeutic avenue.
Study Design
This 26-week, double-blinded, randomized clinical trial will enroll 116 patients diagnosed with Major Depressive Disorder and co-existing overweight or obesity. Participants will receive either once-weekly semaglutide or placebo as an add-on to their usual medication. The primary endpoint is the change in depressive symptoms, quantified by the difference in scores on the 12-item self-report mood questionnaire Major Depression Inventory (MDI) from baseline to follow-up after 26 weeks. The MDI assesses the presence and severity of depressive symptoms over the preceding two weeks.
Results
This entry describes a registered clinical trial protocol, and as such, no results or findings are available yet. The investigators hypothesize that adjunctive treatment with semaglutide will lead to a significant improvement in mood compared to placebo in patients with Major Depressive Disorder and co-existing overweight or obesity. The primary outcome measure, the Major Depression Inventory (MDI), will assess changes in depressive symptoms over 26 weeks. This trial aims to determine if the metabolic benefits of semaglutide translate into measurable improvements in mental health outcomes for this specific patient group.
Why It Matters
If the trial demonstrates positive results, semaglutide could become a valuable adjunctive treatment for MDD patients with co-occurring overweight or obesity, offering a dual benefit for both metabolic health and mood. This would provide clinicians with a novel strategy, potentially improving patient adherence and overall outcomes by addressing interconnected health issues simultaneously. The findings could inform future clinical guidelines and expand the therapeutic utility of GLP-1 agonists beyond metabolic disorders, suggesting a broader role in neuropsychiatric conditions. This could lead to new protocols for patients struggling with both conditions.
semaglutide
major depressive disorder
obesity
overweight
clinical trial
mood
